Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I did not like today's trading too much!
I will point out that we did not yet break yesterday's low and the trend is not yet broken, it's still up.....also the weekly has stayed above the 50 week (1 yr) moving average....
On Balance Volume....excellent on the weekly and holding up on the daily...so stealth buying continues!
Although some are focusing on the Excellence Trial much later this year (August? or later?), I'm thinking that the big issue now will be what happens when Missling exercises his low strike options, 500,000 which expire July 5th.....so I believe he needs a solid news before or latest by then.
Which investment bank would have their clients buy into a company run by a misleader/liar/procrastinator? No bank wants to touch a company that takes 6-12 months after study completion to PR data!
No, it takes them 6 months to get the raw data and another few months to compute endpoints.
You are correct with pointing towards a more respected IB Group with the larger firms or respected Biotech Investment Groups like Baker Bros, etc, but I did note that apparently the founders at LPC were both Harvard Grads and lawyers....also, I did see that 2 of the people there are qualified and specializing in Biotech....
This was a good post as you addressed something that is correct!
It is Rett syndrome NOT Rhett syndrome.
AD/PD°2023
ADVANCES IN SCIENCE & THERAPY
International Conference on Alzheimer's and Parkinson' Diseases and related neurological disorders
March 28 - April 1, 2023
Good luck and GOD bless,
My guess is that due to all the missed milestones, instead of saying Rett data by third quarter, he said 2H to allow for some slippage. Just a hunch but maybe he's learning.
I think all of it in rides on Rhett's. If that gets approved, it'll likely start getting quite a bit off label use which will generate more than Rhett's usage imo. We had great success for an ailment my wife had with off label drug use and it was worth all the hassel and every penny. When someone's back is against the wall, they will try just about anything in their means.
Correction:
The Phase 3 Alzheimer's trial using blarcamesine ia a success that met or exceeded its primary and secondary endpoints with both statistical and clinical significance.
THAT IS A FACT.
Hypothetically, if a company stated that their phase 2b/3 trial met all primary and secondary endpoints and would aggressively pursue approval got wind that another phase 3 trial would be required, then with this insider knowledge, knowing that the share price would likely tank once this is revealed, sells a bunch of shares to raise money, wouldn't that be illegal?
I'll gladly take your shares...
Missling is bad at communicating milestones, but he is good at things that matter more. What will it take for you to admit that?
“Did financing cause he knows they're won't be revenue for a very long time.”
He didn’t do any “financing”. He lined up the equivalent of an equity line of credit. Another arbitrary dot connection.
Rather than trashing CM endlessly (yes, I am also guilty of that), better is to — accept the reality. He is the way he is. We can’t change him, or influence the board to replace him.
Key Q is: Given all the facts, what is the company worth now? Is it worth buying or holding? My take is:
1. AD’s trail as a P2 trial was a success.
2. Rett approval is a serious possibility.
3. Puts company worth $1-2B now, and potential to greatness over next 5 years (with a successful AD P3, which is certainly plausible).
Market seems to like AVXL in this price range — my reading of the recent action. No doubt about it. WHY? Market is certainly the smarter one here.
CM’s ineptness is very frustrating—but perhaps, is a blessing in disguise .. in that, it presents an opportunity?
I personally am slowly reducing my position until the CEO’s ways changes (too disturbing to handle otherwise, for my taste)..
Basparks - I would accept that, but ANVS was up & SAVA was down very little.
Don't know why, but that deal with LPC didn't sit well with me. Hope I'm wrong and we head back up starting tomorrow. We'll see.
This is just NOT TRUE!!!
This is just a distraction and an attempt to spread FEAR, UNCERTAINTY and DOUBT into the hearts and minds of shareholders of AVXL.
GOD bless,
Fritzy’s post is accurate
The company needs to be accountable to the shareholders. Clearly missling only cares about scientists. It could take 30 years to get where we need to because he will just dilute without any regard to shareholders.
But fear not he will give himself enough options to prevent his own dilution
Yes, the market has spoken and the whole sector (XBI) sold down today. Such silly conjecture!
Market Has Spoken. They Don't Like This Financing Deal!
Why do we have to be dealing with LPC. It looks bad and makes us look like an OTC operation. Sorry guys, but I am starting to wonder if we're being strung along. What is the next event that can trigger the SP? Seriously. What if we reach March 1st and nothing happens - will people start screaming? I'm beginning to wonder if Fritzy's post is not all wrong. Hoping for the best, but beginning to wonder.
Anavex has made us a lot of money, since 2015... and now about to be the next SoC for a host of CNS disorders. Holding this through approval this year. $$$
When will you actually admit that
Missling stinks? Under what conditions? Bankruptcy? Is that what it will take?
He isn’t even willing to give timeline for milestones. What does that tell you? That its hard?
Why do all other reputable companies give timelines
Where's the lie? They do have $140M for 4 years.
Preparing for more funding, to have when needed, is just good business planning.
Looks like an opportunity to repurchase and perhaps add more shares... which was expected yesterday.
You tell him, Mr. medical school lecturer.
George your boy Missling said new funding would come from Debt financing 2 calls ago. Just got done telling us this week we got $140 M for 4 years. Turns around and does an ATM.
Why shouldn't he be declared a Liar??
Well as expected
—No real news
—No actual endpoint data
—Proof of missling lying/misleading with rett auc comments
—Lack of milestone accomplishments
—New indefinite milestones to avoid responsibility
—delayed pd rett sd fragile x
Leads to dead money
But great management cuz the pr said we met endpoints
It's amazing that you're still a shareholder if you truly believe the crap you post. (We certainly don't.)
FDA approved RSBQ-AUC, right, George? Those liars.
Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
Check out the approved cancer indications for Ketruda. Why can't we get the same for neurological indications for our Blacamesine?
https://www.keytruda.com/how-d/
Scroll down to FDA-Approved Indications.
When that’s all the negative stuff fudsters can come up with, we’re in good shape. Let them think they have that. Pitiful.
Lie with dogs, get fleas. That is the perception of companies that engage with LPC.
Missling does not want to have to put up with serious biotech investors who are going to ask hard questions, demand straight answers, and put his feet to the fire and hold him accountable when he screws up. He’s perfectly happy to have index funds own his stock as well as retail investors who worship at his feet and defend his every utterance without applying any critical thinking.
By all means, trading to make a few bucks on the volatility is perfectly reasonable, but let’s not pretend Missling is going to upend medicine.
If the Anavex story had any validity, then Missling, together with a top investment bank or banks, would be able to put together an “A” list of biotech institutional investors to finance the company long term and give it credibility where today it has precious little. All Anavex would need is a few bellwether investor names (firms like Perception Life Sciences, Janus Life Sciences Fund, and Biotechnology Value Fund) and we’d truly be on our way. The Street’s perception of Anavex would do a 180, from third-tier curiosity to serious player. Likewise, healthcare/business reporters at major news organizations would suddenly take an interest and bring the Anavex story to a much wider audience. Ditto for potential partners.
Would that red herring by any chance be with chocolate sauce?
Looking forward to hearing more from you regarding Set Theory.
May The Flying Spaghetti Monster be with you,
Lincoln Park Capital is a red herring non-issue for AVXL.
https://www.lpcfunds.com/about/
GOD bless,
Hmmmm. Can't be all that bad. In 2018 AVXL stock was in the $3 range, now it is in the $10-$11 range. I guess AVXL is not in the majority of Lincoln Park victims.
Next time see if you can come up with something relevant to AVXL and how it funds its progress.
I agree with everything you said in your post. The worst possible message Missling could send to serious biotech investors is to get back in bed with a vulture investor like LPC. It’s no wonder not a single biotech institutional investor owns this stock and why several of the analysts covering the stock seem to be stepping back. But this is how Missling apparently wants it. With LPC in place, he can avoid scrutiny from knowledgeable, unemotional biotech investors and avoid accountability for missed milestones and other screw ups.
It’s just amazing how powerful an emotion hope is for retail investors and how it can warp one’s perception of reality. After so many years, the MO is both obvious and predictable. Wash, rinse, and repeat year after year after year. It would be funny if it weren’t so sad and so costly, not only to shareholders but to patients.
Remember this: FUD means Facts, Understanding and Data.
Whit your great understanding if the NDA process what do you think Missling could do to speed things up?
Please include scheduling process of FDA meetings, FDA review times, data analysis , lab analysis, clinical trial report process preparation.
Like I said, the market does NOT like this deal with Lincoln Capital. Aren't you tired of losing 7-10% of the value of this stock on any given day? I know I am.
Anavex's blarcamesine and/or Anavex 3-71 can treat and/or prevent ALS (Lou Gehrig's disease)
Sigma-1 receptor maintains ATAD3A as a monomer to inhibit mitochondrial fragmentation at the mitochondria-associated membrane in amyotrophic lateral sclerosis
I would welcome approval by any agency any time without the need for any bragging rights.
Anavex's blarcamesine and/or Anavex 3-71 can be used to treat and/or prevent cardiovascular diseases including pulmonary arterial hypertension (PAH) and atrial fibrillation (AF).
*******************************************************
Missling is a horrible CEO
- Vulture financing - giving finger to WS
- Did financing cause he knows they're won't be revenue for a very long time. WS knows it too and won't touch the dumpster fire.
- Tries to hide the vulture financing - burying it in the Q (last page) - just shady has hell
- Misses every self imposed milestone - his answer on the call Tuesday was a joke = "easy to start trials, hard to finish" So what, your job as the leader of the company is make it happen. Missling just waved his hands in the air and said don't blame me.
- His solution is not to provide any milestone guidance - giving finger to WS
- Every data release is effed up in some way
- I think longs need to entertain the idea that Missling is a grifter and longs are suckers
- I think for planning purposes longs should assume nothing meaningful happens this year with the exception of announcing the need for a Phase 3 trial in AD - putting commercialization in 2028
- Rett data in 2nd half of 2023 means Feb'ish 2024
- I will be getting short asap
Tell you what, if the FDA gives an approval on this AD trial, your remaining five percent chance will not bestow bragging rights.
Why only Until Rett EXCELLENCE?
To me it is now looking more like the 95% chance of PM P3 like Doc settled on at the time of my generous 75%.
I bet they diluted that 158k today that cleared after hours. Nothing like getting right to it and punishing investors.
Followers
|
1073
|
Posters
|
|
Posts (Today)
|
27
|
Posts (Total)
|
463891
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |